Matching articles for "FluMist"
Antiviral Drugs for Seasonal Influenza for 2024-2025
The Medical Letter on Drugs and Therapeutics • December 9, 2024; (Issue 1717)
Influenza is generally a self-limited illness, but
pneumonia, respiratory failure, and death can occur,
especially in persons at increased risk for influenza
complications (see Table 1). Updated information...
Influenza is generally a self-limited illness, but
pneumonia, respiratory failure, and death can occur,
especially in persons at increased risk for influenza
complications (see Table 1). Updated information on
influenza activity and antiviral resistance is available
from the CDC at cdc.gov/flu.
Comparison Chart: Antiviral Drugs for Seasonal Influenza for 2024-2025 (online only)
The Medical Letter on Drugs and Therapeutics • December 9, 2024; (Issue 1717)
...
View the Comparison Chart: Antiviral Drugs for Seasonal Influenza for 2024-2025
In Brief: FluMist Influenza Vaccine for Self-Administration
The Medical Letter on Drugs and Therapeutics • October 28, 2024; (Issue 1714)
FluMist (AstraZeneca), the live-attenuated intranasal
influenza vaccine that has been available for
years for administration by a healthcare provider
in nonpregnant persons 2-49 years old, has now
been...
FluMist (AstraZeneca), the live-attenuated intranasal
influenza vaccine that has been available for
years for administration by a healthcare provider
in nonpregnant persons 2-49 years old, has now
been approved by the FDA for self- or caregiver-administration.
It is expected to be available for such
use during the 2025-2026 influenza season. FluMist
is only available through a healthcare provider
this season. It will continue to be available for
administration by a healthcare provider in the future
Influenza Vaccine for 2024-2025
The Medical Letter on Drugs and Therapeutics • September 16, 2024; (Issue 1711)
Annual vaccination in the US against influenza A and
B viruses is recommended for everyone ≥6 months
old without a contraindication. Influenza vaccines
available in the US for the 2024-2025 season...
Annual vaccination in the US against influenza A and
B viruses is recommended for everyone ≥6 months
old without a contraindication. Influenza vaccines
available in the US for the 2024-2025 season are
listed in Table 2.
Influenza Vaccine for 2023-2024
The Medical Letter on Drugs and Therapeutics • October 16, 2023; (Issue 1687)
Annual vaccination in the US against influenza A and
B viruses is recommended for everyone ≥6 months
old without a contraindication. Influenza vaccines
that are available in the US for the 2023-2024...
Annual vaccination in the US against influenza A and
B viruses is recommended for everyone ≥6 months
old without a contraindication. Influenza vaccines
that are available in the US for the 2023-2024 season
are listed in Table 2.
Influenza Vaccine for 2023-2024
The Medical Letter on Drugs and Therapeutics • October 16, 2023; (Issue 1687)
Annual vaccination in the US against influenza A and
B viruses is recommended for everyone ≥6 months
old without a contraindication. Influenza vaccines
that are available in the US for the 2023-2024...
Annual vaccination in the US against influenza A and
B viruses is recommended for everyone ≥6 months
old without a contraindication. Influenza vaccines
that are available in the US for the 2023-2024 season
are listed in Table 2.
Antiviral Drugs for Influenza for 2022-2023
The Medical Letter on Drugs and Therapeutics • November 28, 2022; (Issue 1664)
Influenza is generally a self-limited illness, but
complications such as pneumonia, respiratory
failure, and death can occur, especially in patients
at increased risk for influenza complications (see
Table...
Influenza is generally a self-limited illness, but
complications such as pneumonia, respiratory
failure, and death can occur, especially in patients
at increased risk for influenza complications (see
Table 1). Antiviral drugs recommended for treatment
and chemoprophylaxis of influenza this season are
listed in Table 2. Updated information on influenza
activity and antiviral resistance is available from the
CDC at www.cdc.gov/flu. None of the drugs that are
FDA-approved for treatment of influenza have clinically
relevant antiviral activity against SARS-CoV-2.
Comparison Chart: Antiviral Drugs for Influenza for 2022-2023 (online only)
The Medical Letter on Drugs and Therapeutics • November 28, 2022; (Issue 1664)
...
View the Comparison Chart: Antiviral Drugs for Influenza for 2022-2023
Influenza Vaccine for 2022-2023
The Medical Letter on Drugs and Therapeutics • October 3, 2022; (Issue 1660)
Annual vaccination in the US against influenza A and
B viruses is recommended for everyone ≥6 months
old without a contraindication. Influenza vaccines
that are available in the US for the 2022-2023...
Annual vaccination in the US against influenza A and
B viruses is recommended for everyone ≥6 months
old without a contraindication. Influenza vaccines
that are available in the US for the 2022-2023 season
are listed in Table 2.
Antiviral Drugs for Influenza for 2021-2022
The Medical Letter on Drugs and Therapeutics • January 10, 2022; (Issue 1641)
Influenza is generally a self-limited illness, but
complications such as pneumonia, respiratory
failure, and death can occur, especially in patients
at higher risk for complications (see Table 1).
Antiviral...
Influenza is generally a self-limited illness, but
complications such as pneumonia, respiratory
failure, and death can occur, especially in patients
at higher risk for complications (see Table 1).
Antiviral drugs recommended for treatment and
chemoprophylaxis of influenza this season are listed
in Table 2. Updated information on influenza activity
and antiviral resistance is available from the CDC at
www.cdc.gov/flu.
Comparison Chart: Antiviral Drugs for Influenza for 2021-2022 (online only)
The Medical Letter on Drugs and Therapeutics • January 10, 2022; (Issue 1641)
...
View the Comparison Chart: Antiviral Drugs for Influenza for 2021-2022
Influenza Vaccine for 2021-2022
The Medical Letter on Drugs and Therapeutics • October 4, 2021; (Issue 1634)
Annual vaccination against influenza A and B viruses
is recommended for everyone ≥6 months old without a
contraindication.1 Available influenza vaccines for the
2021-2022 season are listed in Table...
Annual vaccination against influenza A and B viruses
is recommended for everyone ≥6 months old without a
contraindication.1 Available influenza vaccines for the
2021-2022 season are listed in Table 2.
Antiviral Drugs for Influenza for 2020-2021
The Medical Letter on Drugs and Therapeutics • November 2, 2020; (Issue 1610)
Influenza is generally a self-limited illness, but
complications such as pneumonia, respiratory failure,
and death can occur, especially in patients at increased
risk for influenza complications (see Table...
Influenza is generally a self-limited illness, but
complications such as pneumonia, respiratory failure,
and death can occur, especially in patients at increased
risk for influenza complications (see Table 1).
Antiviral drugs recommended for treatment and
chemoprophylaxis of influenza this season are listed
in Table 2. Updated information on influenza activity
and antiviral resistance is available from the CDC at
www.cdc.gov/flu.
Influenza Vaccine for 2020-2021
The Medical Letter on Drugs and Therapeutics • September 21, 2020; (Issue 1607)
Annual vaccination against influenza A and B viruses
is recommended for everyone ≥6 months old without a
contraindication. Vaccination of all eligible persons can
reduce the prevalence of influenza illness...
Annual vaccination against influenza A and B viruses
is recommended for everyone ≥6 months old without a
contraindication. Vaccination of all eligible persons can
reduce the prevalence of influenza illness and symptoms
that might be confused with those of COVID-19.
Available vaccines and recommendations for specific
patient populations for the 2020-2021 season are listed
in Tables 2 and 3. Lower rates of influenza illness have
been observed this season in the Southern Hemisphere,
probably because of masking, social distancing, school
closures, and travel restrictions.
Antiviral Drugs for Influenza
The Medical Letter on Drugs and Therapeutics • January 13, 2020; (Issue 1589)
Influenza is generally a self-limited illness, but
pneumonia, respiratory failure, and death can occur.
FDA-approved antiviral drugs for influenza are listed
in Table 2. The neuraminidase inhibitors...
Influenza is generally a self-limited illness, but
pneumonia, respiratory failure, and death can occur.
FDA-approved antiviral drugs for influenza are listed
in Table 2. The neuraminidase inhibitors oseltamivir
(Tamiflu, and generics), which is taken orally, and
zanamivir (Relenza), which is inhaled, are approved
for prophylaxis and treatment of acute uncomplicated
influenza. The IV neuraminidase inhibitor peramivir
(Rapivab) and the oral polymerase acidic (PA)
endonuclease inhibitor baloxavir marboxil (Xofluza)
are approved only for treatment. All of these drugs
are active against both influenza A and influenza B
viruses. Updated information on influenza activity
and antiviral resistance is available from the CDC at
www.cdc.gov/flu.
Influenza Vaccine for 2019-2020
The Medical Letter on Drugs and Therapeutics • October 21, 2019; (Issue 1583)
Annual vaccination against influenza A and B
viruses is recommended for everyone ≥6 months old
without a contraindication. Available vaccines and
recommendations for specific patient populations for
the...
Annual vaccination against influenza A and B
viruses is recommended for everyone ≥6 months old
without a contraindication. Available vaccines and
recommendations for specific patient populations for
the 2019-2020 season are listed in Tables 2 and 3.
Antiviral Drugs for Treatment and Prophylaxis of Seasonal Influenza
The Medical Letter on Drugs and Therapeutics • January 14, 2019; (Issue 1563)
Antiviral drugs can be used for treatment and
prophylaxis of seasonal influenza (see Table 1).
Frequently updated information on influenza activity,
influenza testing, and antiviral resistance is...
Antiviral drugs can be used for treatment and
prophylaxis of seasonal influenza (see Table 1).
Frequently updated information on influenza activity,
influenza testing, and antiviral resistance is available
from the CDC at www.cdc.gov/flu.
Influenza Vaccine for 2018-2019
The Medical Letter on Drugs and Therapeutics • October 22, 2018; (Issue 1558)
Routine annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old. Recommendations for the current season for specific patient populations are listed in Tables 2 and...
Routine annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old. Recommendations for the current season for specific patient populations are listed in Tables 2 and 4.
Antiviral Drugs for Seasonal Influenza 2017-2018
The Medical Letter on Drugs and Therapeutics • January 1, 2018; (Issue 1537)
Antiviral drugs can be used for treatment and prophylaxis
of influenza. Frequently updated information on
influenza activity, testing for influenza, and antiviral
resistance is available from the CDC at...
Antiviral drugs can be used for treatment and prophylaxis
of influenza. Frequently updated information on
influenza activity, testing for influenza, and antiviral
resistance is available from the CDC at www.cdc.gov/flu.
Influenza Vaccine for 2017-2018
The Medical Letter on Drugs and Therapeutics • October 9, 2017; (Issue 1531)
Routine annual vaccination against influenza A and B
viruses is recommended for everyone ≥6 months old
without a specific...
Routine annual vaccination against influenza A and B
viruses is recommended for everyone ≥6 months old
without a specific contraindication.
Influenza Vaccine for 2016-2017
The Medical Letter on Drugs and Therapeutics • October 10, 2016; (Issue 1505)
Annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old without a specific...
Annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old without a specific contraindication.
Influenza Vaccine for 2015-2016
The Medical Letter on Drugs and Therapeutics • September 14, 2015; (Issue 1477)
Annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old without a specific...
Annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old without a specific contraindication.
Peramivir (Rapivab): An IV Neuraminidase Inhibitor for Treatment of Influenza
The Medical Letter on Drugs and Therapeutics • February 2, 2015; (Issue 1461)
The FDA has approved peramivir (Rapivab – BioCryst),
an IV neuraminidase inhibitor administered as a single
dose, for treatment of acute uncomplicated influenza in
patients ≥18 years old who have had...
The FDA has approved peramivir (Rapivab – BioCryst),
an IV neuraminidase inhibitor administered as a single
dose, for treatment of acute uncomplicated influenza in
patients ≥18 years old who have had symptoms for no
more than 2 days. Peramivir was available temporarily
in the US during the 2009-2010 influenza season
under an emergency use authorization for treatment of
hospitalized patients. It has been available in some Asian
countries since 2010. Peramivir is the third neuraminidase
inhibitor to be approved in the US. Oseltamivir
(Tamiflu), which is taken orally, and zanamivir (Relenza),
which is inhaled, are approved for prophylaxis and
treatment of influenza in children and adults.
Antiviral Drugs for Seasonal Influenza 2014-2015
The Medical Letter on Drugs and Therapeutics • December 8, 2014; (Issue 1457)
Antiviral drugs can be used for treatment of influenza
and as an adjunct to influenza vaccination for prophylaxis.
Frequently updated information on influenza
activity and antiviral resistance is available...
Antiviral drugs can be used for treatment of influenza
and as an adjunct to influenza vaccination for prophylaxis.
Frequently updated information on influenza
activity and antiviral resistance is available from the
CDC at www.cdc.gov/flu.
Influenza Vaccine for 2014-2015
The Medical Letter on Drugs and Therapeutics • October 13, 2014; (Issue 1453)
Annual vaccination against influenza A and B viruses
has been shown to decrease influenza illness and...
Annual vaccination against influenza A and B viruses
has been shown to decrease influenza illness and its
complications.
Adult Immunization
The Medical Letter on Drugs and Therapeutics • June 1, 2014; (Issue 142)
Vaccines recommended for adults residing in the
US are reviewed here. Vaccines for travel have been
reviewed separately.
Eight vaccines are currently recommended by the US Advisory Committee on...
Vaccines recommended for adults residing in the
US are reviewed here. Vaccines for travel have been
reviewed separately.
Eight vaccines are currently recommended by the US Advisory Committee on Immunization Practices (ACIP) for routine use in adults at various ages...
Eight vaccines are currently recommended by the US Advisory Committee on Immunization Practices (ACIP) for routine use in adults at various ages...
Antiviral Drugs for Influenza 2013-2014
The Medical Letter on Drugs and Therapeutics • January 20, 2014; (Issue 1434)
Antiviral drugs can be used for treatment of influenza and
as an adjunct to influenza vaccination for prophylaxis. Frequently
updated information on antiviral resistance is available
at...
Antiviral drugs can be used for treatment of influenza and
as an adjunct to influenza vaccination for prophylaxis. Frequently
updated information on antiviral resistance is available
at www.cdc.gov.
Influenza Vaccine for 2013-2014
The Medical Letter on Drugs and Therapeutics • September 16, 2013; (Issue 1425)
Annual vaccination against influenza A and B viruses
has been shown to decrease influenza illness and its
complications. Several new vaccines are available for
the current...
Annual vaccination against influenza A and B viruses
has been shown to decrease influenza illness and its
complications. Several new vaccines are available for
the current season.
Antiviral Drugs for Influenza 2012-2013
The Medical Letter on Drugs and Therapeutics • December 10, 2012; (Issue 1405)
Antiviral drugs can be used as an adjunct to
vaccination for prophylaxis and treatment of influenza.
In recent years, the susceptibility of circulating influenza
virus strains has evolved rapidly and...
Antiviral drugs can be used as an adjunct to
vaccination for prophylaxis and treatment of influenza.
In recent years, the susceptibility of circulating influenza
virus strains has evolved rapidly and treatment recommendations
have changed during the influenza season.
Frequently updated information on antiviral resistance is
available at www.cdc.gov/flu/professionals/antivirals.
Influenza Vaccine for 2012-2013
The Medical Letter on Drugs and Therapeutics • October 1, 2012; (Issue 1400)
Annual vaccination against influenza A and B viruses
is the most effective method of preventing influenza
and has been shown to decrease influenza illness and
its complications. A new vaccine is available...
Annual vaccination against influenza A and B viruses
is the most effective method of preventing influenza
and has been shown to decrease influenza illness and
its complications. A new vaccine is available for the
current season. Chemoprophylaxis and treatment of
influenza was discussed in an earlier issue.
Adult Immunizations
The Medical Letter on Drugs and Therapeutics • December 1, 2011; (Issue 112)
Vaccines recommended for routine use in US adults
are reviewed here. Vaccines for travel have been
reviewed...
Vaccines recommended for routine use in US adults
are reviewed here. Vaccines for travel have been
reviewed separately.
Influenza Vaccine for 2011-2012
The Medical Letter on Drugs and Therapeutics • October 17, 2011; (Issue 1375)
Annual vaccination against influenza A and B viruses
is the most effective method of preventing influenza
and has been shown to decrease influenza illness
and complications. For the current season, a...
Annual vaccination against influenza A and B viruses
is the most effective method of preventing influenza
and has been shown to decrease influenza illness
and complications. For the current season, a new
inactivated intradermal vaccine (Fluzone Intradermal)
has been FDA-approved for use in adults 18-64 years
old. An upcoming issue will review chemoprophylaxis
and treatment of influenza.
Seasonal Trivalent Influenza Vaccine for 2010-2011
The Medical Letter on Drugs and Therapeutics • October 4, 2010; (Issue 1348)
Annual vaccination against influenza A and B viruses is
the most effective method of preventing influenza. An
upcoming issue of The Medical Letter will review drugs
for chemoprophylaxis and treatment of...
Annual vaccination against influenza A and B viruses is
the most effective method of preventing influenza. An
upcoming issue of The Medical Letter will review drugs
for chemoprophylaxis and treatment of influenza.
Antiviral Drugs for Influenza
The Medical Letter on Drugs and Therapeutics • November 16, 2009; (Issue 1325)
Currently circulating influenza virus is almost universally pandemic 2009 influenza A H1N1, but seasonal influenza strains could also appear soon. Antiviral drugs are an important adjunct to influenza...
Currently circulating influenza virus is almost universally pandemic 2009 influenza A H1N1, but seasonal influenza strains could also appear soon. Antiviral drugs are an important adjunct to influenza vaccination for treatment and chemoprophylaxis of both pandemic and seasonal influenza. They may, however, interfere with the efficacy of FluMist, the live-attenuated intranasal vaccine, if they are administered within 48 hours before or <2 weeks after FluMist administration. Inactivated vaccines are not affected by antiviral drug therapy.
Seasonal Trivalent Influenza Vaccine for 2009-2010
The Medical Letter on Drugs and Therapeutics • September 21, 2009; (Issue 1321)
Two separate influenza vaccines will be available this season: the usual seasonal trivalent vaccine and a monovalent vaccine (not yet licensed by the FDA) directed at the novel H1N1 virus currently causing...
Two separate influenza vaccines will be available this season: the usual seasonal trivalent vaccine and a monovalent vaccine (not yet licensed by the FDA) directed at the novel H1N1 virus currently causing pandemic infection. The next issue of the Medical Letter will review the pandemic H1N1 vaccine.
Adult Immunization
The Medical Letter on Drugs and Therapeutics • April 1, 2009; (Issue 80)
Although immunization programs have produced high vaccination rates in US infants and children, similar successes have not been achieved in adults. Vaccines recommended for routine use in adults are reviewed...
Although immunization programs have produced high vaccination rates in US infants and children, similar successes have not been achieved in adults. Vaccines recommended for routine use in adults are reviewed here. Vaccines for travel are reviewed separately.
Influenza Vaccine 2008-2009
The Medical Letter on Drugs and Therapeutics • October 6, 2008; (Issue 1296)
Annual immunization against influenza A and B is the most effective method of preventing infection and has been shown to reduce influenza complications. Changes this year include a vaccine with three new...
Annual immunization against influenza A and B is the most effective method of preventing infection and has been shown to reduce influenza complications. Changes this year include a vaccine with three new influenza antigens and expanded age criteria to include all children 6 months to 18 years of age. An upcoming issue of The Medical Letter will review drugs for prophylaxis and treatment of influenza.
Influenza Vaccine 2007-2008
The Medical Letter on Drugs and Therapeutics • October 8, 2007; (Issue 1271)
Annual immunization against influenza A and B is the most effective method of preventing infection and has been shown to reduce associated complications....
Annual immunization against influenza A and B is the most effective method of preventing infection and has been shown to reduce associated complications.
Influenza Vaccine 2006-2007
The Medical Letter on Drugs and Therapeutics • October 9, 2006; (Issue 1245)
Annual immunization against influenza A and B is the most effective method of preventing infection and has been shown to reduce associated...
Annual immunization against influenza A and B is the most effective method of preventing infection and has been shown to reduce associated complications.
Adult Immunization
The Medical Letter on Drugs and Therapeutics • July 1, 2006; (Issue 47)
Although immunization programs have produced high vaccination rates in US infants and children, similar successes have not been achieved in adults. Vaccines recommended for routine use in adults are reviewed...
Although immunization programs have produced high vaccination rates in US infants and children, similar successes have not been achieved in adults. Vaccines recommended for routine use in adults are reviewed here. Immunizations for travel were reviewed in a recent issue.
Antiviral Drugs for Prophylaxis and Treatment of Influenza
The Medical Letter on Drugs and Therapeutics • November 21, 2005; (Issue 1222)
Antiviral prophylaxis is indicated for influenza exposures that occur before (or less than 2 weeks after) vaccination with inactivated vaccine, or in years when circulating strains differ from those included in...
Antiviral prophylaxis is indicated for influenza exposures that occur before (or less than 2 weeks after) vaccination with inactivated vaccine, or in years when circulating strains differ from those included in the vaccine. Antiviral drugs can also be used for treatment of patients who develop symptoms of influenza, regardless of vaccination status.
Please see Update: Influenza Resistance to Amantadine and Rimantadine
Please see Update: Influenza Resistance to Amantadine and Rimantadine
Influenza Vaccine 2005-2006
The Medical Letter on Drugs and Therapeutics • October 24, 2005; (Issue 1220)
Annual immunization against influenza A and B is the most effective method of preventing infection and has been shown to reduce associated complications. A future issue of The Medical Letter will review drug...
Annual immunization against influenza A and B is the most effective method of preventing infection and has been shown to reduce associated complications. A future issue of The Medical Letter will review drug prophylaxis and treatment of influenza.
Antiviral Drugs for Prophylaxis and Treatment of Influenza
The Medical Letter on Drugs and Therapeutics • October 25, 2004; (Issue 1194)
Due to the unanticipated shortage in the US supply of inactivated influenza vaccine, many persons who normally would have received the vaccine will be unable to get it this year. Antiviral drugs can be used...
Due to the unanticipated shortage in the US supply of inactivated influenza vaccine, many persons who normally would have received the vaccine will be unable to get it this year. Antiviral drugs can be used for prophylaxis of unvaccinated persons who are exposed to influenza, and for treatment of both vaccinated and unvaccinated patients who develop symptoms of the disease.
Influenza Vaccine 2004-2005
The Medical Letter on Drugs and Therapeutics • October 11, 2004; (Issue 1193)
Last year influenza season began in October, peaked in December (both much earlier than usual), and was associated with severe disease, particularly in children. Much of the illness was due to a circulating...
Last year influenza season began in October, peaked in December (both much earlier than usual), and was associated with severe disease, particularly in children. Much of the illness was due to a circulating influenza A H3N2 strain (Fujian type) that had drifted antigenically from the H3N2 strain in the vaccine. The vaccine for the 2004-05 influenza season includes A/Wyoming/3/2003 (H3N2), which is antigenically equivalent to the Fujian strain, A/New Caledonia/20/99 (H1N1), which is unchanged, and a new B strain, either B/Jiangsu/10/2003 or B/Jilin/20/2003, which are both antigenically equivalent to B/Shanghai/361/2002.
FluMist: An Intranasal Live Influenza Vaccine - Addendum
The Medical Letter on Drugs and Therapeutics • February 16, 2004; (Issue 1176)
Addendum: FluMist Storage: The storage requirements for FluMist, the intranasal live-attenuated influenza vaccine (Medical Letter 2003; 45:65) have changed. New data have shown that frost-free freezers are...
Addendum: FluMist Storage: The storage requirements for FluMist, the intranasal live-attenuated influenza vaccine (Medical Letter 2003; 45:65) have changed. New data have shown that frost-free freezers are appropriate for storage for at least 3 months, without need for a freezer-box insert.
Influenza Prevention 2003-2004
The Medical Letter on Drugs and Therapeutics • September 29, 2003; (Issue 1166)
Unlike the last few years there is no early-season shortage of influenza vaccine. Immunization programs for all recommended individuals can proceed. There are 2 new influenza vaccine formulations available...
Unlike the last few years there is no early-season shortage of influenza vaccine. Immunization programs for all recommended individuals can proceed. There are 2 new influenza vaccine formulations available this year, FluMist, an intranasal vaccine and Fluzone, a pediatric formulation. Timing, indications, adverse effects, dosage and cost of the vaccines is discussed. The drugs that can be used for prophylaxis of influenza are also reviewed.
FluMist: An Intranasal Live Influenza Vaccine
The Medical Letter on Drugs and Therapeutics • August 19, 2003; (Issue 1163)
FluMist (MedImmune), the first live-attenuated and first intranasally administered influenza vaccine, has been approved by the FDA to prevent influenza in healthy people 5-49 years old. Given as a nasal spray,...
FluMist (MedImmune), the first live-attenuated and first intranasally administered influenza vaccine, has been approved by the FDA to prevent influenza in healthy people 5-49 years old. Given as a nasal spray, it stimulates immunity by viral replication in the upper respiratory tract. This vaccine apparently will be advertised directly to the public as a "needle-free" alternative to intramuscular influenza vaccine.